China · Delayed Price · Currency is CNY WuXi AppTec Earnings Call Transcripts
Fiscal Year 2026
-
Record 2025 revenue and profit were driven by strong demand in GLP-1, peptides, and small molecules, with significant capacity expansions and robust global customer growth. The company maintained high ESG standards, returned substantial value to shareholders, and expects continued growth in 2026.
Fiscal Year 2025
-
Record 2025 results with revenue up 21.4% and adjusted net profit up 41.3% year-over-year. 2026 guidance targets 18–22% revenue growth, robust cash flow, and continued global expansion, supported by a strong backlog and resilient business model.
-
Record revenue and profit growth in the first three quarters, driven by strong performance in small molecule and TIDES businesses, with robust backlog and improved margins. Raised full-year guidance, accelerated global expansion, and announced divestiture of China-based clinical research services.
-
Record first-half revenue and profit driven by strong CRDMO growth, margin expansion, and robust U.S. demand. Full-year guidance was raised, with significant capital returns to shareholders and continued global capacity expansion planned.
-
Q1 2025 saw double-digit revenue and profit growth, with strong performance in Chemistry and TIDES segments, while Testing faced pricing pressure. Full-year guidance is maintained despite global uncertainties, with robust capital allocation and continued expansion in key markets.
-
The company reported robust growth in revenue, profit, and backlog, driven by its integrated CRDMO model and expanding global capacity. Strong performance in new modalities, especially TIDES and GLP-1, and stable margins reflect operational resilience despite external challenges.